375836-83-2
Chemical Structure
MBX2319
- CAS No.: 375836-83-2
- Formula:C23H27N3O2S
- Molecular Weight:409.54
InChIKey: CITLGGQQUFMBKB-UHFFFAOYSA-N
SMILES: N#CC1=C(SCCC2=CC=CC=C2)N=C(N3CCOCC3)C4=C1CC(C)(C)OC4
Biological Activity: MBX2319 is an AcrB inhibitor and antibiotic efficacy restorer that potently inhibits RND-type efflux pumps of Enterobacteriaceae species. MBX2319 increases antibacterial activity of fluoroquinolone and β-lactam antibiotics against Escherichia coli, restores antibiotic efficacy, and reduces antibiotic MIC against Gram-negative bacteria. MBX2319 has no inherent antibacterial activity against Escherichia coli and does not alter bacterial outer membrane permeability. MBX2319 can be used for the research of gram-negative bacterial infections and multidrug-resistant gram-negative bacterial infections[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MBX2319 | MBX2319 is an AcrB inhibitor and antibiotic efficacy restorer that potently inhibits RND-type efflux pumps of Enterobacteriaceae species. MBX2319 increases antibacterial activity of fluoroquinolone and β-lactam antibiotics against Escherichia coli, restores antibiotic efficacy, and reduces antibiotic MIC against Gram-negative bacteria. MBX2319 has no inherent antibacterial activity against Escherichia coli and does not alter bacterial outer membrane permeability. MBX2319 can be used for the research of gram-negative bacterial infections and multidrug-resistant gram-negative bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nguyen ST, et al. Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorganic & medicinal chemistry. 2015 May 01;23(9):2024-34. [Content Brief]
- [2]. Vargiu AV, et al. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrobial agents and chemotherapy. 2014 Oct;58(10):6224-34. [Content Brief]
